Monovalent Anti-Properdin Antibodies to Limit Immune Complex Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effectively regulating properdin activity to mitigate diseases associated with alternative complement pathway dysregulation, as uncontrolled activation can lead to systemic inflammation and tissue damage.
Innovation Solution
Development of monovalent antibodies and antibody fragments that specifically bind to properdin, inhibiting its functional activity and blocking the alternative complement pathway activation, thereby reducing undesirable immune complexes and improving clinical outcomes for patients with diseases mediated by alternative complement pathway dysregulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bivalent antibodies are used to bind properdin, then binding affinity is improved, but immune complex aggregation and toxicity increase
Solution Approach 1:
The patent divides the bivalent antibody into separate monovalent antibody fragments (such as Fab fragments or single-domain antibodies), each capable of binding one properdin molecule independently. This segmentation prevents the formation of large immune complexes while maintaining effective binding affinity through high concentrations of monovalent units.
Solution Approach 2:
The patent extracts the Fc region from the complete antibody structure, retaining only the antigen-binding variable regions (Fab fragments or VHH domains). This extraction eliminates the Fc-mediated aggregation and complement activation that cause toxicity, while preserving the essential properdin-binding function in the variable regions.
2Reliability
If properdin activity is not regulated, then alternative complement pathway activation occurs, but systemic inflammation and tissue damage result
Solution Approach 1:
The patent applies preliminary anti-action by using monovalent antibodies to preemptively block properdin's stabilizing interaction with C3 convertase before uncontrolled complement activation can occur. This prevents the downstream inflammatory cascade while avoiding the harmful aggregation effects of bivalent antibodies.
3Object-generated harmful factors
If monovalent antibodies are used to bind properdin, then immune complex aggregation is reduced, but binding valency decreases
Solution Approach 1:
The patent employs monovalent antibody fragments that, while individually univalent, achieve multivalent-like effects through high local concentration and cooperative binding. The monovalent fragments can simultaneously engage multiple properdin molecules in different locations, achieving effective pathway blockade without the aggregation problems of traditional bivalent antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monovalent antibodies effectively inhibit alternative complement pathway-induced membrane attack complex assembly, reducing immune complex aggregation and providing therapeutic benefits for a range of diseases associated with alternative complement pathway dysregulation.
Implementation Method 1
isolated monovalent antibodies and antibody fragments thereof that specifically or substantially specifically bind properdin
Implementation Method 2
By inhibiting the functional activity of properdin, the monovalent antibody described herein inhibits alternative complement pathway-induced assembly of the membrane attack complex
Implementation Method 3
selective binding of a single properdin molecule with a monovalent antibody can reduce undesirable immune complexes, resulting from aggregation
Data Source
AI summary
Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin. Such antibodies are useful in methods of treatment for diseases mediated by alternative complement pathway dysregulation.